Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay
Starting soon
Conditions studied: T-Cell Lymphoproliferative Disorder
In brief
This protocol describes the pivotal accuracy study for the IdentiClone Dx TRG Assay. The intent of the accuracy study is to demonstrate agreement between the results of the IC TRG Dx Assay and a predicate devise or assay on retrospective and residual de-identified DNA extracted from FFPE (Formalin Fixed Paraffin Embedded) samples from individuals with suspected T-Cell Lymphoproliferations. The predicate device will be the LymphoTrack Dx TRG (FR1/FR2/FR3) Assays - MiSeq (LT Dx TRG-CE-IVD), which is a CE-IVD assay with a similar intended use as the IC TRG Assay on the same sample type.
Key facts
- Study ID
- NCT06876571
- Run by
- Invivoscribe, Inc.
- People needed
- 250
- Starts
- 2025-06-02
- Expected to finish
- 2025-12-06
- Last updated by the study team
- 2025-03-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- De-identified, residual FFPE specimens with a minimum of 8 curls
- Subject Age ≥ 18
- For suspected clonal positive specimens, FFPE specimens of subjects diagnosed (at the time the specimen was drawn) with T-cell Lymphoproliferative disease with at least one of the following:
- ICD10 Codes: C84, C85.8, C85.9, C86.1, C86.2, C86.3, C86.5, 86.6, C91.5, C91.6, C91.0, C91.z, C91.9, C94, C95, C96, or other T-cell lymphoma diagnosis
- b. T-cell lymphoproliferative disease diagnosis per collection site procedure (e.g., SNOMED)
- Mycosis fungoides or Sézary syndrome sample are acceptable
- For suspected clonal negative specimens, FFPE specimens of subjects suspected of T-cell lymphoproliferative disease but diagnosed negative for T-cell lymphoproliferative disease. Up to 20% of the negative specimens may be from normal tissue or tissue diagnosed with diseases other than T-cell lymphoproliferative disease
You may not qualify if…
- FFPE specimens that were fixed using formalin substitute (ethanol, methanol, etc.)
Where it is running
- Invivoscribe, Inc. — San Diego, California, United States
- LabPMM GmbH — Hallbergmoos, Germany
- LabPMM GK — Kawasaki-shi, Kanagawa, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.